A pandemic focus on a notorious protein
During the COVID-19 pandemic, Gabriela Dias Noske and other researchers at the University of Sao Paulo — like scientists all over the world — shifted their research projects toward the SARS-CoV-2 virus. Dias Noske was working with proteases at the time, so she pivoted to the main protease of the virus and worked to assess its structural features for drug design.

The research was not without its challenges, especially during the pandemic, with lab resources scarce and inaccessible at times.
“It was very demanding because we were working with no weekends and no holidays, just working with only four people in the lab to keep the lab working,” Dias Noske said. “But it was a very nice thing to be able to be there and doing something for a pandemic.”
The main protease, or Mpro, of the SARS-CoV-2 virus is an important protein in disease progression. Dias Noske and colleagues sought to determine the structural basis of antivirals such as nirmatrelvir and ensitrelvir and how these drugs inhibit Mpro and its mutations.
Dias Noske conducted activity-based screening assays and structural data analysis using crystallographic data. She found many key interactions between the antivirals and the Mpro mutations, which will aid in developing the next generation of antivirals that inhibit Mpro and its mutations.
For published in the Journal of Biological Chemistry, Dias Noske received a 2024 .
A physics major during her undergraduate studies, Dias Noske decided to specialize in biomolecular physics in grad school. She began by using crystallography to solve the crystal structure of viral proteins. Having worked on several viruses during her doctoral studies, she is now working on cryo-electron tomography, imaging virus–host interactions within cells using a microscope.
Mutations and drug activity
Antivirals are used to inhibit viral replication and stop the progression of viral diseases like COVID-19. Researchers need to understand the structure and mutations of Mpro as it is a crucial part of viral replication and can cause antiviral resistance.
Gabriela Dias Noske and a team at the University of Sao Paulo studied 14 naturally occurring polymorphs of Mpro against the antivirals nirmatrelvir and ensitrelvir to understand the key interactions in protein inhibition. They showed that there were changes in potency — the amount of drug required for a desired effect. The drug–target interactions were confined to a specific binding site, where the drug binds to a number of amino acid residues in the protein sequence. Changes in the structure within the binding site affect drug interactions, and the drug loses its ability to cause a desired response.
Activity-based screening assays compared potency for the 14 mutants and wild-type Mpro for the two drugs. Nirmatrelvir showed slightly lower potency for most of the polymorphs, and ensitrelvir showed significantly lower potency with respect to the wild type. The data also suggest a distinctive binding profile for the two drugs.
Enjoy reading 91ÑÇÉ«´«Ã½ Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from 91ÑÇÉ«´«Ã½ Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in People
People highlights or most popular articles

Hidden strengths of an autistic scientist
Navigating the world of scientific research as an autistic scientist comes with unique challenges —microaggressions, communication hurdles and the constant pressure to conform to social norms, postbaccalaureate student Taylor Stolberg writes.

Richard Silverman to speak at 91ÑÇÉ«´«Ã½ 2025
Richard Silverman and Melissa Moore are the featured speakers at the 91ÑÇÉ«´«Ã½ annual meeting to be held April 12-15 in Chicago.

Women’s History Month: Educating and inspiring generations
Through early classroom experiences, undergraduate education and advanced research training, women leaders are shaping a more inclusive and supportive scientific community.

91ÑÇÉ«´«Ã½ honors Lawrence Tabak with public service award
He will deliver prerecorded remarks at the 2025 91ÑÇÉ«´«Ã½ Annual Meeting in Chicago.

91ÑÇÉ«´«Ã½ names 2025 JBC/Tabor Award winners
The six awardees are first authors of outstanding papers published in 2024 in the Journal of Biological Chemistry.

Daniel N. Hebert (1962–2024)
Daniel Hebert’s colleagues remember the passionate glycobiologistscientist, caring mentor and kind friend.